Breast Cancer Test Breakthrough

A groundbreaking international trial has revealed that a genomic test can identify millions of breast cancer patients who can safely skip chemotherapy.

The Prosigna test analyzes tumor genes to determine if hormone therapy alone is sufficient, potentially sparing thousands from harsh side effects.

This breakthrough could revolutionize breast cancer treatment, offering a less aggressive approach for many patients.

Meanwhile, concerns about a breast cancer scandal in Durham are growing, as revealed in a High Court document.